Genentech initiates study on subcutaneous ocrelizumab for MS patients switching from anti-CD20 therapy
Genentech is conducting a study to evaluate subcutaneous ocrelizumab in MS patients switching from approved anti-CD20 therapies.
Asset / Drug
Drug and asset intelligence for Ocrelizumab with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.